特集: 調査項目の変更・追加が可能なセミカスタムオーダー型の調査レポート(Lucintel社)はこちら

特集 : 国別の市場調査レポートをお探しの方はこちら

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

日本のジェネリック医薬品市場展望

Japan Generics Drug Market Outlook 2020

発行 KuicK Research 商品コード 356382
出版日 ページ情報 英文 66 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=108.13円で換算しております。

ご注意: DRM (デジタル著作権管理システム) 付PDFになります。制限内容はお問合せください。
Multi-User License: 会社全体での使用権

日本のジェネリック医薬品市場展望 Japan Generics Drug Market Outlook 2020
出版日: 2016年04月19日 ページ情報: 英文 66 Pages
概要

当レポートでは、日本のジェネリック医薬品市場について調査し、市場の概要、市場の魅力度、日本の医療制度、米国と日本のジェネリック医薬品比較、市場の分析、および展望など、体系的な情報を提供しています。

第1章 日本のジェネリック医薬品市場のイントロダクション

  • 日本のジェネリック医薬品の成長理由
  • 日本におけるジェネリック医薬品関連の主な誤解

第2章 日本のジェネリック医薬品の魅力

  • 日本の医薬品市場の概要
  • 日本のジェネリック医薬品市場の特徴
  • 日本のジェネリック医薬品企業
  • 日本におけるジェネリック医薬品の輸入
  • ジェネリック医薬品に関する経済的な視点

第3章 日本におけるジェネリック医薬品の状況

  • 日本におけるジェネリック医薬品価格の状況
  • 日本における医薬品特許の各分類
  • 日本におけるジェネリック医薬品のプロモーション

第4章 日本におけるスーパージェネリック医薬品

  • スーパージェネリック医薬品のイントロダクション
  • スーパージェネリック医薬品のメリット
  • スーパージェネリック医薬品のデメリット

第5章 日本におけるジェネリック医薬品・先発医薬品の各パラメーター

  • 日本における特許保護
  • 日本の医療費への影響
  • ジェネリック医薬品に対する日本の薬理学的パラメーター
  • 規制要件の違い
  • 日本市場における先発医薬品・ジェネリック医薬品の活用

第6章 日本におけるジェネリック医薬品の医薬品有効成分 (API)

  • 医薬品有効成分 (API) の登録
  • 日本における外国企業の規制
  • ジェネリックAPIの製造能力

第7章 日本における健康およびジェネリック医薬品の利用

  • 日本における癌の発生率
  • 日本における糖尿病発生率の増加
  • 日本における心血管疾患発生率の増加
  • 日本における心血管疾患の発生率
  • 日本における汚染が原因の疾患

第8章 日本における医療制度およびジェネリック医薬品

  • 万能な医療保険
  • 物価上昇の管理
  • ジェネリック医薬品の品質管理
  • ジェネリック医薬品市場へのアクセス
  • 日本におけるジェネリック医薬品の特許に関連した問題
  • 日本におけるジェネリック医薬品の普及を抑制する要因

第9章 米国・日本におけるジェネリック医薬品の比較

  • ジェネリック医薬品の規制の枠組み
  • ジェネリック医薬品の市場浸透率
  • ジェネリック医薬品の価格
  • ジェネリック医薬品の認知

第10章 日本におけるジェネリック医薬品市場の分析

第11章 日本におけるジェネリック医薬品市場の好ましい要因

  • 人口高齢化
  • ジェネリック医薬品規制
  • ハイテク能力
  • 疾患発生率の上昇

第12章 日本におけるジェネリック医薬品商業化の課題

  • 日本の規制環境
  • ジェネリック医薬品に対する態度
  • ジェネリック医薬品の受け入れの低さ
  • 相容れない特許法

第13章 日本におけるジェネリック医薬品市場の将来の見通し

第14章 競合環境

  • Actavis
  • エーザイ
  • 富士薬品
  • GlaxoSmithKline
  • Hospira
  • Meiji Seika ファルマ
  • 日医工
  • ニプロファーマ
  • Pfizer
  • 沢井製薬
  • 武田薬品工業
  • 東和薬品

図表

目次

Japan is a small island nation located in East Asia and it is known for its economic prosperity. It sports one of the largest pharmaceutical markets like US and Europe due to which immense commercialization opportunities are present. Unique demographic structure and presence of advanced technology is the main reason for the growth of Japanese pharmaceutical industry. They have one of the most advanced research and development facilities across the world contributing significantly to the development of healthcare infrastructure. Japan has opened its pharmaceutical market for foreign trade leading to higher input of drugs. Their population is going in downward spiral where number of young people are lesser then geriatric population. In this way, they have high demand for therapeutic products due which their pharmaceutical market is increasing.

Observation shows that Japanese pharmaceuticals market is heavily inclined towards consumption of branded drugs. Due to presence of higher technological capabilities they were able to commercialize innovative drugs. Significant investments were made in research and development segment due to which new products are being made. It promoted the utilization of branded drugs in Japanese market. Presence of universal healthcare system also allowed the patients to include generic drugs in their therapeutic regime. They to invest small out of pocket money while buying branded drugs as rest of the part is covered by the universal healthcare system. Branded drugs market got boost due to regulator's policies but these drugs are quite costly. As a result, stagnant economy is not able to sustain burgeoning financial pressure on healthcare system.

Japanese generic drugs market is largely unchurned due to which it offers significant commercialization opportunities. Both domestic and foreign pharmaceutical companies are expected to take advantage of this scenario. Japanese regulators have developed amenable rules due to which foreign pharmaceutical companies can venture in generic drugs segment. This will increase the competition and further decrease the prices of generic drugs in Japanese market. Moreover, it will build a strong supply chain due to which dearth of generic drugs will not occur in future. Regulators will also be able to increase their consumption by promoting more numbers of patients opting for the generic drugs. In this way, they will be able to observe decrease in investments in healthcare system. To achieve higher cost savings, more work has yet to be done in coming years.

Prices of both generic and branded drugs are checked by Japanese regulators after every two years. This allows the patients to spend less money for treatment of their diseases in long-term scenario. But it could be observed that patients are not willing to switch to the generic drugs despite lesser cost. Main reason behind this fact is that cost difference between these drugs is not significant. Higher buying power of patients allow them to include costly branded drugs in their daily therapeutic regime. This scenario shows that Japanese regulators have to further decrease the prices of generic drugs in order to offer higher cost arbitrage. They also have to increase the uptake of generic drugs in order to decrease the prevalence of branded drugs as major component of healthcare system. Some of the measures have been implemented but their results are yet to be observed in coming years.

Japanese pharmaceuticals market is quite mature and still has opportunities for growth as they have lesser market shares of generic drugs. This allows significant potential to generic firms to enter in Japanese pharmaceuticals market. Presence of amenable regulation and significant efforts made to decrease healthcare spending is expected to take place in coming years. Large geriatric population plays an important role of consumers in Japanese pharmaceutical industry. They require long-term usage of drugs and switching them from branded to generic drugs will boost the market. It also offers significant commercialization opportunities as compared to other countries where generic drugs occupy major market shares. Japanese generic drugs market is expected to grow several folds in coming years, in this way, its future looks optimistic.

“Japan Generics Drug Market Outlook 2020” Report Highlights:

  • Introduction to Japanese Generic Drug Market
  • Attractiveness of Japanese Generic Market
  • Super Generics in Japan
  • Japan Healthcare System & Generic Drugs
  • Different Parameters for Generic & Branded Drugs
  • Comparison of Generic Drugs in US & Japan
  • Japan Generics Drug Market Analysis
  • Japan Generics Drug Market Future Prospects

Table of Contents

1. Introduction to Japan Generic Drug Market

  • 1.1 Reasons for Growth of Japan Generic Market
  • 1.2 Some Misconceptions Related to Generic Drugs in Japan

2. Attractiveness of Japan Generic Market

  • 2.1 Overview of Japan Pharmaceutical Market
  • 2.2 Features of Japan Generic Drugs Market
  • 2.3 Generic Drug Firms in Japan
  • 2.4 Generic Drugs Import in Japan
  • 2.5 Economic Views about Generic Drugs

3. Scenario of Generic Drugs in Japan

  • 3.1 Scenario for Generic Drug Discount Price in Japan
  • 3.2 Different Categories of Pharmaceutical Patent in Japan
  • 3.3 Promotion of Generic Drugs in Japan

4. Super Generics in Japan

  • 4.1 Introduction to Super Generics
  • 4.2 Advantages of Super Generics
  • 4.3 Disadvantages of Super Generics

5. Different Parameters for Generic & Branded Drugs in Japan

  • 5.1 Patent Protection in Japan
  • 5.2 Effect on Japan Healthcare Spending
  • 5.3 Japan Pharmacological Parameters for Generic Drugs
  • 5.4 Difference in Regulatory Requirements
  • 5.5 Utilization of Branded & Generic Drugs in Japan Market

6. Generic Active Pharmaceutical Ingredients in Japan

  • 6.1 Generic Active Pharmaceutical Ingredient Registration
  • 6.2 Regulation for Foreign Companies in Japan
  • 6.3 Manufacturing Capabilities for Generic API 7. Health in Japan & Utilization of Generic Drugs
  • 7.1 Cancer Incidences in Japan
  • 7.2 Increasing Diabetes Incidences in Japan
  • 7.3 Increasing Cerebrovascular Incidences in Japan
  • 7.4 Cardiovascular Diseases Incidences in Japan
  • 7.5 Disease Caused by Pollution in Japan

8. Healthcare System & Generic Drugs in Japan

  • 8.1 Universal Healthcare Coverage
  • 8.2 Price Rise Control
  • 8.3 Quality Control of Generic Drugs
  • 8.4 Access to Generic Market
  • 8.5 Patents Related Issues to Generic Drugs in Japan
  • 8.6 Factors Restricting Uptake of Generic Drugs in Japan

9. Comparison of Generic Drugs in US & Japan

  • 9.1 Regulatory Framework for Generic Drugs
  • 9.2 Market Penetration of Generic Drugs
  • 9.3 Prices of Generic Drugs
  • 9.4 Perception towards Generic Drugs

10. Japan Generic Drugs Market Analysis

11. Japan Generic Market Favorable Factors

  • 11.1 Ageing Population
  • 11.2 Generic Drugs Regulations
  • 11.3 High Technological Capabilities
  • 11.4 Increasing Disease Incidences

12. Japan Generics Market Commercialization Challenges

  • 12.1 Japan Regulatory Environment
  • 12.2 Attitude towards Generic Drugs
  • 12.3 Lower uptake of Generic Drugs
  • 12.4 Conflicting Patent Laws

13. Japan Generic Drugs Market Future Prospects

14. Competitive Landscape

  • 14.1 Actavis
  • 14.2 Eisai
  • 14.3 Fuji Pharma
  • 14.4 GlaxoSmithKline
  • 14.5 Hospira
  • 14.6 Meiji Seika Pharma
  • 14.7 Nichi-Iko Pharmaceutical
  • 14.8 Nipro Pharma
  • 14.9 Pfizer
  • 14.10 Sawai Pharmaceuticals
  • 14.11 Takeda Pharmaceutical
  • 14.12 Towa Pharmaceutical

List of Figures

  • Figure 1-1: Reasons for Growth of Japan Generic Market
  • Figure 1-2: Some Steps taken by Japan Regulators to Decrease Drug Prices
  • Figure 1-3: Some Misconceptions Related to Generic Drugs in Japan
  • Figure 2-1: Some Considerations while Approaching Japan Generic Market
  • Figure 3-1: Discount Determination of Generic Drugs in Japan
  • Figure 3-2: Type of Drug Price Survey in Japan
  • Figure 4-1: Advantages of Super Generics
  • Figure 4-2: Disadvantages of Super Generics
  • Figure 5-1: Economic Benefits of opting Generic Drugs
  • Figure 5-2: Regulatory Requirement for Generic Drugs in Japan
  • Figure 5-3: Utilization of Branded and Generic Drugs in Japan Market
  • Figure 6-1: Requirements for Registration of API
  • Figure 6-2: Regulation for Foreign Companies in Japan
  • Figure 6-3: Japan - Manufacturing Capabilities for Generic API
  • Figure 7-1: Aim of Basic Plan to Promote Cancer Control Programs
  • Figure 7-2: Estimated Numbers of Cancer Cases in Japan, 2015
  • Figure 8-1: Position of Generics in Japan Healthcare System
  • Figure 8-2: Patents Related Issues to Generic Drugs in Japan
  • Figure 10-1: Japan - Generics Drug Market (US$ & Yen), 2014-2016
  • Figure 10-2: Japan - Generics Drug Share in Pharmaceutical Market (%), 2014
  • Figure 11-1: Japan - Generic Drugs Market Drivers
  • Figure 12-1: Japan - Generics Market Commercialization Challenges
  • Figure 13-1: Japan - Generics Drug Market (US$ & Yen), 2017-2020
  • Figure 13-2: Japan - Generics Drug Share of Prescription Drug (%), 2018
  • Figure 13-3: Japan - Generics Drug Share of Prescription Drug (%), 2020
  • Figure 13-4: Japan - Generics Drug Share in Pharmaceutical Market (%), 2020

List of Tables

  • Table 1-1: Some Important Features of Japan
  • Table 3-1: Listing Period for Various Drugs in Japan
  • Table 5-1: Difference between Branded and Generic Drugs in Japan
  • Table 5-2: Regulatory Requirements for Different Drugs in Japan
  • Table 7-1: Estimated Numbers of Different Cancer Affecting Japan Population, 2015
  • Table 7-2: Estimated Numbers of Males Affected by Different Type of Cancer in Japan, 2015
  • Table 7-3: Estimated Numbers of Females Affected by Different Type of Cancer in Japan, 2015
  • Table 7-4: Issues related with Cerebrovascular Diseases
  • Table 7-5: Some Important Diseases caused by Pollutants in Japan
  • Table 9-1: Difference in Regulatory Framework between Japan & US